CoChat

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor

Open access
Johns, Douglas G., Campeau, Louis-Charles, Banka, Puja, Bautmans, An, Bueters, Tjerk, Bianchi, Elisabetta, Branca, Danila, Bulger, Paul G., Crevecoeur, Inne, Ding, Fa-Xiang, Garbaccio, Robert M., Guetschow, Erik D., Guo, Yan, Ha, Sookhee N., Johnston, Jennifer M., Josien, Hubert, Kauh, Eunkyung A., Koeplinger, Kenneth A., Kuethe, Jeffrey T., Lai, Eseng, Lanning, Christine L., Lee, Anita Y.H., Li, Li, Nair, Anilkumar G., O’Neill, Edward A., Stoch, S. Aubrey, Thaisrivongs, David A., Tucker, Thomas J., Vachal, Petr, van Dyck, Kristien, Vanhoutte, Frederic P., Volckaert, Bram, Wolford, Dennis G., Xu, Andy, Zhao, Tian, Zhou, Dan, Zhou, Susan, Zhu, Xiaohong, Zokian, Hratch J., Walji, Abbas M., Wood, Harold B. · 2023 · Circulation
Cited by 167

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Background: Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9)-low density lipoprotein receptor interaction with injectable monoclonal antibodies or small interfering RNA lowers plasma low density lipoprotein-cholesterol, but despite nearly 2 decades of effort, an oral inhibitor of PCSK9 is not available. Macrocyclic peptides represent a novel approach to target proteins traditionally considered intractable to small-molecule drug design. Methods: Novel mRNA display screening technology was used to identify lead chemical matter, which was then optimized by applying structure-based drug design enabled by novel synthetic chemistry to identify macrocyclic peptide (MK-0616) with exquisite potency and selectivity for PCSK9. Following completion of nonclinical safety studies, MK-0616 was administered to healthy adult participants in a single rising-dose Phase 1 clinical trial designed to evaluate its safety, pharmacokinetics, and pharmacodynamics. In a multiple-dose trial in participants taking statins, MK-0616 was administered once daily for 14 days to characterize the safety, pharmacokinetics, and pharmacodynamics (change in low density lipoprotein cholesterol). Results: MK-0616 displayed high affinity ( K i = 5pM) for PCSK9 in vitro and sufficient safety and oral bioavailability preclinically to enable advancement into the clinic. In Phase 1 clinical studies in healthy adults, single oral doses of MK-0616 were associated with >93% geometric mean reduction (95% CI, 84–103) of free, unbound plasma PCSK9; in participants on statin therapy, multiple–oral-dose regimens provided a maximum 61% geometric mean reduction (95% CI, 43–85) in low density lipoprotein cholesterol from baseline after 14 days of once-daily dosing of 20 mg MK-0616. Conclusions: This work validates the use of mRNA display technology for identification of novel oral therapeutic agents, exemplified by the identification of an oral PCSK9 inhibitor, which has the potential to be a highly effective cholesterol lowering therapy for patients in need.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.122.063372

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 167

Metadata

Authors
Johns, D. G., Campeau, L.-C., Banka, P., Bautmans, A., Bueters, T., Bianchi, E., Branca, D., Bulger, P. G., Crevecoeur, I., Ding, F.-X., Garbaccio, R. M., Guetschow, E. D., Guo, Y., Ha, S. N., Johnston, J. M., Josien, H., Kauh, E. A., Koeplinger, K. A., Kuethe, J. T., Lai, E., Lanning, C. L., Lee, A. Y. H., Li, L., Nair, A. G., O’Neill, E. A., Stoch, S. A., Thaisrivongs, D. A., Tucker, T. J., Vachal, P., van Dyck, K., Vanhoutte, F. P., Volckaert, B., Wolford, D. G., Xu, A., Zhao, T., Zhou, D., Zhou, S., Zhu, X., Zokian, H. J., Walji, A. M., & Wood, H. B.
Venue
Circulation
Published
2023-07-11
Volume
148
Issue
2
Pages
144-158
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W4367602059
Cited by
167
References
8
FWCI
39.83
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor. https://app.cochat.ai/papers/10.1161/circulationaha.122.063372
The paper
Johns, D. G., Campeau, L.-C., Banka, P., Bautmans, A., Bueters, T., Bianchi, E., Branca, D., Bulger, P. G., Crevecoeur, I., Ding, F.-X., Garbaccio, R. M., Guetschow, E. D., Guo, Y., Ha, S. N., Johnston, J. M., Josien, H., Kauh, E. A., Koeplinger, K. A., Kuethe, J. T., . . . Wood, H. B. (2023). Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor. Circulation. https://doi.org/10.1161/circulationaha.122.063372

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.